Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies

Sub-indication: Miscellaneous Malignancies

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Tizona Therapeutics, Inc.

Learn more at ClinicalTrials.gov

Email for more information: MISC-NCIResearch@Nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.